2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P3375
    Mazdutide 2259884-03-0 99.74%
    Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D).
    Mazdutide
  • HY-107725
    BIBO3304 191868-14-1 99.96%
    BIBO3304 is a potent, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist, with subnanomolar affinity for both the human and the rat Y1 receptor (IC50=0.38 and 0.72 nM, respectively).
    BIBO3304
  • HY-113679
    Ceramides Mixture 100403-19-8 ≥99.0%
    Ceramides Mixture is an endogenous ceramide and consists of hydroxy and non-hydroxy fatty acid-containing ceramides. Ceramides Mixture is a main lipid component of the permeability barrier in epidermis. Ceramides Mixture is involved in the regulation of growth inhibition, cell cycle arrest, and modulation of telomerase activity.
    Ceramides Mixture
  • HY-120912
    Gingerenone A 128700-97-0 99.95%
    Gingerenone A is an Nrf2-Gpx4 activator that can induce Ferroptosis in liver damage with oral activity. Gingerenone A has anti-inflammatory, anti-diabetic, anti-tumor, and pro-aging effects in mice.
    Gingerenone A
  • HY-124293
    AA147 393121-74-9 99.81%
    AA147 is a endoplasmic reticulum (ER) proteostasis regulator. AA147 promotes protection against oxidative damage in neuronal cells and prevents endothelial barrier dysfunction by activating ATF6 arm (selectively) of the unfolded protein response (UPR) and the NRF2 oxidative stress response. AA147 can rebalances XBP1s expression in vivo, and also induces survival motor neuron (SMN) expression and spinal motorneuron (MN) protection.
    AA147
  • HY-125818
    Cytidine-5'-triphosphate 65-47-4 ≥98.0%
    Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.
    Cytidine-5'-triphosphate
  • HY-153347
    JY-2 339103-05-8 99.75%
    JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity.
    JY-2
  • HY-W010832
    Uridine-5'-diphosphate disodium salt 27821-45-0 ≥99.0%
    Uridine-5'-diphosphate disodium salt is a potent, selective P2Y6 receptor native agonist (EC50=300 nM; pEC50=6.52 for human P2Y6 receptor). Uridine-5'-diphosphate disodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis.
    Uridine-5'-diphosphate disodium salt
  • HY-W015611
    L-(+)-Arabinose 5328-37-0 ≥99.0%
    L-(+)-Arabinose selectively inhibits intestinal sucrase activity in a noncompetitive manner and suppresses the plasma glucose increase due to sucrose ingestion.
    L-(+)-Arabinose
  • HY-10007
    NPS-2143 284035-33-2 99.94%
    NPS-2143 (SB-262470A), an orally active calcilytic agent, is a selective and potent calcium ion-sensing receptor (CaSR) antagonist. NPS-2143 (SB-262470A) blocks increases in cytoplasmic Ca2+ concentrations (IC50=43 nM) elicited by activating the Ca2+ receptor in HEK 293 cells expressing the human Ca2+ receptor.
    NPS-2143
  • HY-B0258
    Gemfibrozil 25812-30-0 99.91%
    Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
    Gemfibrozil
  • HY-N0022
    Isoacteoside 61303-13-7 99.73%
    Isoacteoside is a natural product that can significantly inhibit the formation of glycation end products. Isoacteoside regulates the AKT/PI3K/m-TOR/NF-κB signaling pathway, induces apoptosis in OVCAR-3 cell. Isoacteoside exhibits antitumor, anti-inflammatory, anti-obesity and neuroprotective activities.
    Isoacteoside
  • HY-P10798
    Eloralintide 2883634-40-8 99.90%
    Eloralintide (LY 3841136) is an AMYR agonist, which is promising for research of type 2 diabetes and obesity.
    Eloralintide
  • HY-13009
    PF-04620110 1109276-89-2 99.60%
    PF-04620110 is a potent, selective and orally bioavailable diglyceride acyltransferase-1 (DGAT-1) inhibitor with an IC50 of 19 nM.
    PF-04620110
  • HY-P1141
    GLP-1(9-36)amide 161748-29-4 99.69%
    GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor.
    GLP-1(9-36)amide
  • HY-108241
    (Z)-PUGNAc 132489-69-1 ≥99.0%
    (Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form.
    (Z)-PUGNAc
  • HY-128374
    D-Glucose 6-phosphate disodium salt 3671-99-6 ≥98.0%
    D-Glucose-6-phosphate disodium salt is a glucose sugar phosphorylated at the hydroxy group on carbon 6.
    D-Glucose 6-phosphate disodium salt
  • HY-Y0479S
    L-Lactic acid-13C3 87684-87-5 ≥99.0%
    L-Lactic acid-13C3 is a 13C-labeled L-Lactic acid (HY-Y0479). L-Lactic acid-13C3 can be used for lactate metabolism research.
    L-Lactic acid-13C3
  • HY-111431A
    p-Cresyl sulfate potassium 91978-69-7 ≥98.0%
    p-Cresyl sulfate potassium is a uremic toxin that binds to a prototype protein. p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways. p-Cresyl sulfate potassium has pro-inflammatory activity.
    p-Cresyl sulfate potassium
  • HY-W018512
    7-Ketolithocholic acid 4651-67-6 ≥98.0%
    7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion.
    7-Ketolithocholic acid
Cat. No. Product Name / Synonyms Application Reactivity